Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Bevacizumab in Rare Solid Tumors
NCT03074513Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2017
- Primary completion
- Sep 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in Appendix adenocarcinoma, anal squamous cell carcinoma (SCCA), cervical squamous cell carcinoma (CSCC), penile squamous cell carcinoma (PSCC), vulvar squamous cell carcinoma (VSCC), sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2017; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
Appendix adenocarcinomaanal squamous cell carcinoma (SCCA)cervical squamous cell carcinoma (CSCC)penile squamous cell carcinoma (PSCC)vulvar squamous cell carcinoma (VSCC)
Beyond the preview
Go deeper on NCT03074513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03074513.